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Introduction
EGF is a growth factor that stimulates the proliferation of fibroblasts and most types of epithelial cells. The receptor for EGF is a transmembrane glycoprotein with tyrosine kinase activity (1) . Many human epithelial tumors have been found to express high numbers of EGF receptors (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , and increased receptor levels are associated with a poor clinical prognosis in cancers involving the bladder (6, 9) , breast (6, 7) , and lung (10, 11) . Furthermore, EGF receptor activation has been implicated in autocrine stimulation of cell growth in many experimental studies (12) . Therefore, the EGF receptor appears to be an excellent target for antitumor therapy.
We have produced and characterized two mAbs against the human EGF receptor, 225 IgGi and 528 IgG2a (13, 14) . They bind to the EGF receptor with affinity similar to the natural ligands, EGF and TGF-a, compete with ligands for receptor binding, and inhibit ligand-induced activation of receptor tyrosine kinase (13) (14) (15) (16) . The mAbs have been shown to inhibit proliferation of a variety of cultured tumor cell lines that express EGF receptors and TGF-a, including vulva (13) (14) (15) , breast (17, 18) , colon (19, 20) , lung (21) , renal (22) , and prostate (23) cells. Inhibition of cell growth has been suggested to result from blockade of EGF receptor activation by growth factor either present in the culture medium or produced by the cells in an autocrine fashion (24) (25) (26) . The mAbs are also able to prevent the growth of EGF receptor-bearing human tumor xenografts in nude mice (20, 24, (27) (28) (29) . The initial phase I clinical trials with these mAbs demonstrated the safety of administering 225 mAb in doses adequate to image tumors and to maintain blood levels > 30 nM (receptor-saturating concentrations) for more than 3 d (30) .
Insulin and IGF-1 are closely related polypeptides with respect to their amino acid sequences, three-dimensional structures, and range of biological activities (31) . Their corresponding receptors are similar in their subunit structure and molecular size, and they display cross-reactivity in response to high concentrations of ligand (32) (33) (34) . Both EGF receptors and IGF-1 receptors belong to the family of tyrosine protein kinases, and they have been shown to phosphorylate some proteins in common (35) . It also has been shown that both EGF and IGF-1 can regulate proliferation of the same cells (36) . mAb 225 can successfully prevent the growth of human tumor xenografts in nude mice treated at an early stage, within a week of inoculation, but fail to do so against well-established xenografts of most cell lines tested (27) . An exception is the DiFi colorectal adenocarcinoma cell line, which displays the highest sensitivity to mAb 225 of all cell lines studied. Wellestablished xenografts of DiFi cells are completely eradicated after mAb treatment (20) . DiFi cells were derived from a patient with a hereditary colorectal carcinoma. They secrete TGFa and express high numbers of membrane-associated EGF receptors (4.8 X 106 receptors/cell) (37, 38) . The reasons why DiFi cells are extremely sensitive to inhibition by mAb 225 were explored.
Programmed cell death, or apoptosis, is a mode of cell death that plays an important role in embryonic development, metamorphosis, organ involution, and tumor growth kinetics. Events associated with this process include activation of a Ca2 -dependent endonuclease (39) and internucleosomal fragmentation of genomic DNA, resulting in formation of a ladder of DNA fragments (40) (41) (42) . DNA fragmentation is followed by characteristic morphological changes that involve chromatin condensation, nuclear disintegration, and cellular fragmentation into membrane-bound apoptotic bodies (43, 44) . In the present studies, DiFi cells were examined both biochemically and morphologically after mAb 225 treatment. We found that apoptosis could be induced by mAb 225, which blocks EGF receptor tyrosine kinase. Insulin, or IGF-1, which activates the tyrosine kinase activity of IGF-1 receptors, could delay mAb 225-induced apoptosis. Cell cycle arrest in G1 phase also was induced by mAb 225 treatment, but this response to EGF receptor blockade was unaffected by either insulin or IGF-1. The results show that regulation of cell cycle traversal and regulation of apoptosis are separable, and that common pathway(s) activated by both EGF receptors and IGF-1 receptors may be involved in inhibition of apoptosis in these cells.
Methods
Materials. mAb 225 was produced in this laboratory and has been previously described (13, 14) . Cell cycle analysis. Trypsinized cells were washed with serum-free DME/F12 medium twice. Cells were resuspended at 106 cells/ml in propidium iodide solution (5 mM MgCl2, 10 mM Tris-HCl, pH 7.6, 0.5% NP-40, 50 jig/ml propidium iodide, and 100 ug/ml RNase A) and incubated for 30 min at 37°C. Cell cycle analysis was then performed on a FACScanO flow cytometer (Becton Dickinson and Co., Cockeysville, MD).
Results
Induction of cell cycle arrest and apoptosis by mAb 225. Blockade of cell growth by mAb 225 results in cytostatic rather than cytocidal effects in most human tumor cell lines studied (13) (14) (15) (16) . To probe the mechanism of the high sensitivity of DiFi cells to mAb 225 treatment, cell growth kinetics were examined in response to varying doses of mAb 225 (Fig. 1) . With 1 nM mAb 225, there was inhibition of growth in comparison with (Fig. 2 B) . There was a clear relationship between the amount of fragmented DNA and the concentration of mAb 225. Fig. 3 demonstrates the typical morphological changes induced by treatment with mAb 225. Compared with the untreated cells (Fig. 3 A) , DiFi cells treated with 10 nM mAb 225 for 48 h showed a reduction in cell volume, condensation of nuclear chromatin, and the appearance of nuclear fragmentation (Fig.  3 B) (Fig. 4 B) . Interestingly, insulin could also delay cell death caused by mAb 225. As shown in Fig. 4 To confirm that mAb 225-induced apoptosis was delayed by addition of growth factor, the formation of DNA internucleosomal ladders was examined after 1 d of treatment (Fig. 4 C) . 10 nM mAb 225 alone induced a clear DNA ladder, while the addition of either EGF or insulin together with mAb 225 prevented formation of the ladder, suggesting that mAb 225-induced apoptosis was rescued by each growth factor. Treatment with EGF alone, in the absence of mAb, resulted in formation of a very faint DNA ladder.
Effect of EGF and insulin/lIGF-I on mAb 225-mediated cell cycle arrest. Addition of EGF in concentrations equivalent to mAb 225 could completely prevent the GI arrest induced by mAb 225 (Table I) . However, addition of either insulin or IGF-1 with mAb 225 did not influence the mAb 225-mediated cell cycle arrest after 24 h exposure, at which time the mAb 225-induced apoptosis was effectively delayed by insulin/IGF-l. In the absence of mAb, insulin/IGF-1 alone had no influence on the cell cycle phase distribution, and EGF by itself decreased the fraction of cells in GI phase.
The existence of two RB protein forms that differ in phosphorylation states has been noted previously in most cell types (48, 49 7.5% SDS-PAGE. After transfer to a nitrocellulose membrane, the proteins were blotted with PY69 and autoradiographed. most cells were in early and mid-GI phase. Addition of EGF together with mAb 225 could prevent this conversion of RB phosphorylation states, while neither insulin nor IGF-1 could do so. EGF or insulin/IGF-l alone, in the absence of mAb, had no effect on RB phosphorylation states. We conclude that incubation of DiFi cells with mAb 225 prevents phosphorylation of RB and induces an early to mid-GI phase arrest, which can be prevented by coaddition of EGF but not insulin/IGF-l.
Delay of mAb 225-mediated apoptosis by insulin/lIGF-I is mediated by the IGF-J receptor. Ligand-induced receptor tyrosine kinase activation is reflected by autophosphorylation of the receptor on tyrosine residues. In Fig. 6 ined by immunoblot after various treatments for 24 h. The observed basal level of tyrosine phosphorylation resulted from autocrine stimulation by TGF-a. mAb 225 caused reduction of EGF receptor autophosphorylation that could be attributed to both blocking of receptor tyrosine kinase activation and downregulation of receptors (Fig. 6 A) . EGF stimulated tyrosine phosphorylation, and it greatly downregulated the number of receptors. Insulin/IGF-l had no effect on EGF receptor level or tyrosine phosphorylation. When EGF was combined with mAb 225 in equimolar amounts, it reversed the block in phosphorylation caused by mAb 225. In contrast, insulin/IGF-l failed to reverse the block in phosphorylation caused by mAb 225. Therefore, it can be concluded that EGF reverses the induction of apoptosis by mAb 225 through competitively binding to and activating EGF receptors, while insulin/IGF-l delays mAb-mediated apoptosis through a mechanism that does not involve the EGF receptor.
IGF-1 receptors are highly expressed in DiFi cells, as detected by immunoblot (data not shown). To determine the tyrosine phosphorylation status of IGF-l receptors after stimulation by either EGF or insulin/IGF-l, IGF-1 receptors were first immunoprecipitated with aIR3 mAb and subsequently immunoblotted with antiphosphotyrosine antibody (Fig. 6 B) . The results show that both insulin and IGF-1 can activate IGF-1 receptor tyrosine phosphorylation, while EGF has no effect on IGF-1 receptor phosphorylation. It was therefore important to know if IGF-l receptor activation is a requirement for the delay in 225 mAb-mediated apoptosis caused by addition of insulin or IGF-1. aIR3 is an mAb against the IGF-1 receptor that can inhibit insulin/IGF-1 binding (50). When aIR3 was used alone, it had little inhibitory effect on DiFi cell growth (Fig. 7) . When it was combined with mAb 225 and insulin/IGF-l, the delay of mAb 225-induced cell death by IGF-1 was completely blocked and the delay by insulin was partially blocked, in a dose-dependent manner. Therefore, in the normal situation, DiFi cell survival relies mainly on activation of the EGF receptor signal transduction pathway rather than the IGF-l pathway. However, if the EGF pathway is inhibited, activation of the IGF-l pathway (or possibly other pathways) can become critical for DiFi cell survival.
Insulin/lIGF-J delay is specific for mAb 225-mediated apoptosis. A variety of physical and chemical agents can induce apoptosis (51) . Though the mechanism of selection of this pathway for cell death is not fully understood, it is clear that cells possess effector mechanisms for self-destruction, which may be activated by several different stimuli. To determine whether insulin delays cell death by acting upon a final common pathway of apoptosis, or whether it specifically delays the apoptosis induced by blocking the EGF receptor signal transduction pathway, the effect of insulin on cell death mediated by cisplatin also was examined (Fig. 8) . Cisplatin is an alkylating agent that produces interstrand and intrastrand base crosslinking in DNA, and it is one of the most active drugs against the human epithelial tumors that express high levels of EGF receptors (52) . The data in Fig. 8 A show that intemucleosomal DNA fragmentation and apoptosis can be induced after 24 h exposure to cisplatin, and that this is concentration dependent. However, in contrast to the delay of mAb 225-mediated cell death by insulin, cell death induced by cisplatin is not prevented by insulin (Fig. 8 B) .
Discussion
Culture of DiFi cells with anti-EGF receptor mAb 225 induced cell cycle arrest in GI phase and apoptosis. Tyrosine phosphorylation of EGF receptors stimulated by either endogenous TGFa (Fig. 6 ) or exogenous EGF (data not shown) was blocked by mAb 225, and this was prevented by coaddition of EGF at (53, 54) . Thus the DiFi cell line displays both shared and unique responses to EGF receptor blockade. To explain the differences, future studies will compare the responses of these malignant and nonmalignant cell lines by assessing both proximal events in EGF receptor-mediated signal transduction and distal events such as mitogen-activated protein kinase activation and cycin-dependent kinase activity.
The well-documented capacity of EGF to inhibit proliferation of cells expressing high levels of EGF receptors is demonstrated in Fig. 4 A (55, 14) . We previously explored the dual inhibition produced by anti-EGF receptor mAb and by EGF in cultures of A431 and MDA468 cells expressing high numbers of receptors (15, 18 (Table I) ; (b) while both mAb and EGF produce cell death, EGF produced only traces of accumulated DNA fragments (Fig. 4 B) and did not cause the morphologic changes characteristic of apoptosis (data not shown); (c) cell death induced by EGF was not delayed by addition of insulin (data not shown). It must be stressed that mAb 225 in either its bivalent or monovalent forms does not activate EGF receptor tyrosine kinase in intact cells (57, 58) , so that the mechanism of mAb action is quite different from that of the growth factor. The results of these experiments suggest that EGF receptors may be critical for cell cycle traversal and cell survival through a number of different mechanisms. They also suggest that DiFi cells require an optimal amount of activity in EGF receptormediated signal transduction pathways for cell proliferation and survival, and that too little or too much activity could be harmful to the cells.
The activity of mAb 225 appears to require bivalency, which confers the capacity to induce receptor dimerization (57, 58) . When experiments were performed with the 225 Fab' monovalent fragment, inhibition of DiFi cell growth was markedly reduced (data not shown). This is comparable to our observation of reduced antiproliferative activity of 225 Fab' against a variety of cell lines (57, 58) .
Insulin, or IGF-1, is able to delay mAb 225-induced apoptosis (Fig. 4) . Unlike rescue with EGF, which competes with mAb 225 for receptor binding and activates tyrosine kinase activity, insulin/IGF-l appears to act through a different mechanism. Insulin/IGF-l can neither activate tyrosine phosphorylation of EGF receptors (Fig. 6 ) nor change EGF receptor levels. IGF-l receptors are expressed in DiFi cells, and their tyrosine kinase activity is activated upon binding of insulin/IGF-l (Fig.  6 ). Monoclonal antibody aIR3, which blocks insulin/IGF-l binding to IGF-1 receptor, can completely inhibit the delay of apoptosis by IGF-1 (Fig. 7) , which suggests that IGF-1 delays mAb 225-mediated apoptosis by binding to and activating IGF-1 receptors. The target protein activated via the IGF-1 receptor may be shared in the signaling pathway activated by the EGF receptor, or it may be unique to the insulin/IGF-1 receptormediated pathway.
It has been observed that EGF may increase IGF-l production, and an important role of EGF in the proliferation of 3T3 fibroblasts is to activate an autocrine loop via the IGF-I receptor (59) . However, EGF action on DiFi cells does not seem to result from increasing IGF-1 production, since IGF-1 receptor tyrosine phosphorylation is not activated after EGF treatment (Fig. 6) , and mAb aIR3 against the IGF-1 receptor does not induce cell death, unlike mAb 225 (Fig. 7) .
Addition of insulin/IGF-1 delayed mAb 225-mediated apoptosis but did not affect GI cell cycle arrest. This suggests that the pathways leading to apoptosis and to G1 cell cycle arrest are separable. EGF receptor-mediated signaling pathways that also can be activated by insulin/IGF-1 may prevent apoptosis, while EGF receptor-mediated signaling pathways that cannot be activated by insulin/IGF-1 may regulate movement through GI phase of the cell cycle. Although the mechanisms that are involved are not clear, the separation of apoptosis and GI cell cycle arrest by the addition of insulin/IGF-l will help to guide our further studies of regulation of both cell cycle traversal and apoptosis.
Unlike EGF, which can completely rescue mAb 225-induced apoptosis, insulin can only delay apoptosis for 48 h and fails to do so after 48 h. The reasons why insulin only delays apoptosis instead of accomplishing a complete rescue are unclear. The failure of prolonged rescue is not due to the degradation of insulin in the medium, as cells die even if fresh insulin is added daily (data not shown). One possibility is that longterm treatment with insulin might downregulate IGF-1 receptors and thereby eliminate their corresponding signal required for cell survival. Alternatively, another slower pathway, unrelated to IGF-1 pathways, may be activated after EGF receptor blockade.
